December 26, 2023 11:24 AM EST

J&J licenses LegoChem's Trop2 ADC for $100M upfront

Katherine Lewin

News Reporter

Johnson and Johnson’s subsidiary Janssen is licensing a Trop2 directed antibody-drug conjugate from South Korea’s LegoChem Biosciences in a deal that could be worth as …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

J&J licenses LegoChem's Trop2 ADC for $100M upfront

Katherine Lewin

News Reporter

Sign up to read this article for free.

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

A look at biotech's year of the megaround

GSK’s Nucala bags another China approval, but biggest test yet to come

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts

J&J li­cens­es LegoChem's Trop2 ADC for $100M up­front

Katherine Lewin

News Reporter

Sign up to read this article for free.

more like this

Af­ter Ca­griSe­ma, eyes are on Lil­ly’s oral GLP-1 as next key obe­si­ty play

Re­gen­eron buys Lon­don-based oc­u­lar biotech

Penn­syl­va­nia Blue Cross in­sur­er re­stricts cov­er­age of med­i­cines grant­ed FDA ac­cel­er­at­ed ap­proval

A look at biotech's year of the megaround

GSK’s Nu­cala bags an­oth­er Chi­na ap­proval, but biggest test yet to come

Bio­phar­ma to raise more than 1,000 drug prices in 2025, ad­vi­so­ry firm pre­dicts

J&J licenses LegoChem's Trop2 ADC for $100M upfront

After CagriSema, eyes are on Lilly’s oral GLP-1 as next key obesity play

Regeneron buys London-based ocular biotech

Pennsylvania Blue Cross insurer restricts coverage of medicines granted FDA accelerated approval

GSK’s Nucala bags another China approval, but biggest test yet to come

Biopharma to raise more than 1,000 drug prices in 2025, advisory firm predicts